TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›RLYB›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Rallybio Corp (RLYB) financials

Income statement

Rallybio Corp (RLYB) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue————$636K$858K
Revenue growth—————34.9%
Operating income-$25.3M-$45.6M-$67.9M-$78.9M-$60.5M-$33.1M
Operating margin————-9511.9%-3853.6%
Net income-$26.4M-$47.0M-$66.7M-$74.6M-$57.8M-$8.98M
Net margin————-9084.1%-1046.4%
EPS (diluted)-$1.52-$1.84-$2.09-$1.84-$10.61-$1.59

Cash flow

Rallybio Corp (RLYB) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$22.0M-$45.5M-$57.3M-$60.3M-$49.3M-$29.8M
Capital expenditures$137K$333K$54.0K$12.0K$0.00—
Free cash flow-$22.2M-$45.9M-$57.3M-$60.3M-$49.3M—

Balance sheet

Rallybio Corp (RLYB) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$140M$175M$57.0M$24.5M$13.9M$31.4M
Total assets$142M$182M$180M$116M$68.1M$62.3M
Total liabilities$5.86M$6.58M$11.1M$9.44M$6.45M$4.30M
Shareholders' equity$136M$176M$169M$106M$61.7M$58.0M
Retained earnings-$47.0M-$94.0M-$161M-$235M-$293M-$302M
Shares (wtd avg diluted)23.4M25.5M31.8M40.4M5.44M5.63M

Every figure is extracted from Rallybio Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Rallybio Corp's annual revenue?
Rallybio Corp (RLYB) reported $858K of revenue for fiscal year 2025 — up 34.9% from $636K in FY2024, per its annual report filed with the SEC.
Is Rallybio Corp profitable?
Not in FY2025 — RLYB reported a net loss of $8.98M, per SEC filings.
Does RLYB pay a dividend?
Rallybio Corp reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full RLYB analysis — verdict, score & filings →Is RLYB a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.